Fasting and cancer: molecular mechanisms and clinical application.

Fasting and cancer: molecular mechanisms and clinical application.
复制标题

DOI:
10.1038/s41568-018-0061-0
复制
发表时间:
2018-11
期刊:
Nature reviews. Cancer
影响因子:
--
通讯作者:
Longo VD
Longo VD
中科院分区:
其他
文献类型:
--
作者:
Nencioni A;Caffa I;Cortellino S;Longo VD

文献摘要

参考文献

被引文献

相似文献

癌细胞对营养缺乏的脆弱性及其对特定代谢物的依赖性是癌症的新标志。禁食或禁食模仿饮食(FMD)导致生长因子和代谢物水平的广泛改变,产生可以降低癌细胞适应和存活能力的环境,从而改善癌症治疗的效果。此外,禁食或FMD增加了正常细胞而不是癌细胞对化疗的抵抗力,并促进了正常组织的再生,这有助于预防治疗的有害和潜在的危及生命的副作用。虽然患者几乎不能耐受禁食,但动物和临床研究表明,低热量FMD周期是可行的,总体上是安全的。一些评估禁食或FMD对治疗后出现的不良事件和疗效结局影响的临床试验正在进行中。我们认为,FMD与化疗、免疫治疗或其他治疗的组合代表了一种潜在的有希望的策略,可以提高治疗效果,防止耐药性获得并减少副作用。
The vulnerability of cancer cells to nutrient deprivation and their dependency on specific metabolites are emerging hallmarks of cancer. Fasting or fasting-mimicking diets (FMDs) lead to wide alterations in growth factors and in metabolite levels, generating environments that can reduce the capability of cancer cells to adapt and survive and thus improving the effects of cancer therapies. In addition, fasting or FMDs increase resistance to chemotherapy in normal but not cancer cells and promote regeneration in normal tissues, which could help prevent detrimental and potentially life-threatening side effects of treatments. While fasting is hardly tolerated by patients, both animal and clinical studies show that cycles of low-calorie FMDs are feasible and overall safe. Several clinical trials evaluating the effect of fasting or FMDs on treatment-emergent adverse events and on efficacy outcomes are ongoing. We propose that the combination of FMDs with chemotherapy, immunotherapy or other treatments represents a potentially promising strategy to increase treatment efficacy, prevent resistance acquisition and reduce side effects.
DOI: 10.1016/j.clnu.2016.07.015
发表时间: 2017-02-01
期刊: CLINICAL NUTRITION
影响因子: 6.3
作者:
Arends, Jann;Bachmann, Patrick;Preiser, Jean-Charles
通讯作者: Preiser, Jean-Charles
DOI: 10.1126/science.1173635
发表时间: 2009-07-10
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Colman RJ;Anderson RM;Johnson SC;Kastman EK;Kosmatka KJ;Beasley TM;Allison DB;Cruzen C;Simmons HA;Kemnitz JW;Weindruch R
通讯作者: Weindruch R
DOI: 10.18632/oncotarget.3689
发表时间: 2015-05-20
期刊: ONCOTARGET
影响因子: --
作者:
Caffa, Irene;D'Agostino, Vito;Nencioni, Alessio
通讯作者: Nencioni, Alessio
DOI: 10.1016/j.cmet.2015.05.012
发表时间: 2015-07-07
期刊: Cell metabolism
影响因子: 29
作者:
Brandhorst S;Choi IY;Wei M;Cheng CW;Sedrakyan S;Navarrete G;Dubeau L;Yap LP;Park R;Vinciguerra M;Di Biase S;Mirzaei H;Mirisola MG;Childress P;Ji L;Groshen S;Penna F;Odetti P;Perin L;Conti PS;Ikeno Y;Kennedy BK;Cohen P;Morgan TE;Dorff TB;Longo VD
通讯作者: Longo VD
DOI: 10.1038/nrclinonc.2012.99
发表时间: 2012-08-01
影响因子: 78.8
作者:
Cleeland, Charles S.;Allen, Jeff D.;Skillings, Jamey
通讯作者: Skillings, Jamey